These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12801117)

  • 1. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation.
    Chan PW; Abdel-Latif ME
    Acta Paediatr; 2003 Apr; 92(4):481-5. PubMed ID: 12801117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.
    Robbins JM; Tilford JM; Jacobs RF; Wheeler JG; Gillaspy SR; Schutze GE
    Arch Pediatr Adolesc Med; 1998 Apr; 152(4):358-66. PubMed ID: 9559712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.
    Thomas M; Bedford-Russell A; Sharland M
    Arch Dis Child; 2000 Aug; 83(2):122-7. PubMed ID: 10906017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
    Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
    Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
    Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
    Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
    Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
    J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk.
    Rietveld E; De Jonge HC; Polder JJ; Vergouwe Y; Veeze HJ; Moll HA; Steyerberg EW
    Pediatr Infect Dis J; 2004 Jun; 23(6):523-9. PubMed ID: 15194833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States.
    Krilov LR; Palazzi DL; Fernandes AW; Klein RW; Mahadevia PJ
    Value Health; 2010; 13(1):77-86. PubMed ID: 19706010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
    Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
    CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis.
    Numa A
    J Paediatr Child Health; 2000 Oct; 36(5):422-7. PubMed ID: 11036794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
    Welliver RC
    Semin Perinatol; 1998 Feb; 22(1):87-95. PubMed ID: 9523402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus: A structural equation modeling approach.
    Sruamsiri R; Kubo H; Mahlich J
    Medicine (Baltimore); 2018 Jul; 97(29):e11491. PubMed ID: 30024527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.
    Kamal-Bahl S; Doshi J; Campbell J
    Arch Pediatr Adolesc Med; 2002 Oct; 156(10):1034-41. PubMed ID: 12361451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.